Document Detail

The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. European Organization for Research and Treatment of Cancer. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.
MedLine Citation:
PMID:  9753069     Owner:  NLM     Status:  MEDLINE    
To determine whether patients with a HLA-identical sibling donor have a better outcome than patients without a donor, an analysis on the basis of intention-to-treat principles was performed within the framework of the EORTC-GIMEMA randomized phase III AML 8A trial. Patients in complete remission (CR) received one intensive consolidation course. Patients with a histocompatible sibling donor were then allocated allogeneic bone marrow transplantation (alloBMT), the patients without a donor were randomized between autologous BMT (ABMT) and a second intensive consolidation (IC2). 831 patients <46 years old and alive >8 weeks from diagnosis were included. HLA typing was performed in 672 patients. AlloBMT was performed during CR1 in 180 (61%) out of 295 patients with a donor. Another 38 patients were allografted: five in resistant disease, 14 during relapse and 19 in CR2. ABMT was performed in 130 (34%) out of 377 patients without a donor in CR1, in six (2%) patients during relapse and in 38 (10%) patients during CR2. The disease-free survival (DFS) from CR for patients with a donor was significantly longer than for patients without a donor (46% v 33% at 6 years; P=0.01, RR 0.78, 95% confidence interval 0.63-0.96). The overall survival from diagnosis for patients with a donor was longer, but not statistically significant, than for patients without a donor (48% v 40% at 6 years; logrank P=0.24). When patients were stratified according to prognostic risk groups, the same trend in favour of patients with a donor was seen for survival duration and the DFS remained significantly longer for this group of patients.
S Keating; T de Witte; S Suciu; R Willemze; M Hayat; B Labar; L Resegotti; P R Ferrini; F Caronia; M Dardenne; G Solbu; M C Petti; M L Vegna; F Mandelli; R A Zittoun
Related Documents :
7514439 - 2chlorodeoxyadenosine therapy of patients with waldenström macroglobulinemia previously...
3312839 - The ucla experience with type i interferons in hairy cell leukemia.
12377969 - Overexpression of the polycythemia rubra vera-1 gene in essential thrombocythemia.
8518029 - Correlation of morphological fab classification and immunophenotyping: value in recogni...
12107559 - Splenectomy in patients with mixed myelodysplastic/myeloproliferative disease.
17252009 - Mutations of the bcr-abl-kinase domain occur in a minority of patients with stable comp...
6232839 - Noninvasive evaluation of the severity of aortic stenosis in adult patients.
21556779 - Tryptophan degradation and neopterin levels in treated rheumatoid arthritis patients.
6093679 - Dna analysis in patients with hereditary fructose intolerance.
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  British journal of haematology     Volume:  102     ISSN:  0007-1048     ISO Abbreviation:  Br. J. Haematol.     Publication Date:  1998 Sep 
Date Detail:
Created Date:  1998-11-17     Completed Date:  1998-11-17     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0372544     Medline TA:  Br J Haematol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1344-53     Citation Subset:  IM    
EORTC Data Centre, Brussels, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bone Marrow Transplantation / methods*
Disease-Free Survival
Histocompatibility Testing
Leukemia, Myeloid, Acute / therapy*
Middle Aged
Prospective Studies
Risk Assessment
Tissue Donors / supply & distribution*
Transplantation Conditioning / methods
Transplantation, Autologous
Treatment Outcome
Grant Support
2U10-CA11488-26/CA/NCI NIH HHS; 5U10-CA11488-19/CA/NCI NIH HHS

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The activating splice mutation in intron 3 of the thrombopoietin gene is not found in patients with ...
Next Document:  Polymorphism in CD33 and CD34 genes: a source of minor histocompatibility antigens on haemopoietic p...